Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05128487 · ClinicalTrials.gov registry record · Phase 1
A Study of NDI 1150-101 in Patients With Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, sponsored by Nimbus Saturn.
- Active
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
- 19
- Study locations
NCT05128487: Active Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, sponsored by Nimbus Saturn.
NCT05128487 is a Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor that is active but no longer recruiting, run by Nimbus Saturn. The registered enrollment target is 106 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (84% lower). The trial reports 19 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05128487, a Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, is active but no longer recruiting, sponsored by Nimbus Saturn.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
- 19
- Study locations
Study Summary
This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as monotherapy or in combination with pembrolizumab in adult patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG NDI-101150
Study Locations (19)
Texas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center - Dallas
- Center for Oncology and Blood Disorders - Houston
- Oncology Consultants - Houston
- NEXT Oncology - San Antonio
Arizona
- Honor Health Research Institute - Scottsdale
Connecticut
- Yale Cancer Center - New Haven
District of Columbia
- Georgetown University - Washington D.C.
Florida
- Ocala Oncology Center - Ocala
Kentucky
- Norton Cancer Institute - Louisville
Maryland
- University of Maryland Greenebaum Comprehensive Cancer Center - Baltimore
Michigan
- Henry Ford Cancer - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2021-11-05 |
| Est. Completion | 2025-05 |
| Phase | Phase 1 |
What the registry record for NCT05128487 still lists
NCT05128487 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (84% lower).
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05128487 lists 19 locations in 16 states (Texas, Arizona, Connecticut).
Frequently Asked Questions
What is clinical trial NCT05128487 about?
NCT05128487 is a clinical study titled "A Study of NDI 1150-101 in Patients With Solid Tumors". This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as monotherapy or in combination with pembrolizumab in adult patients wit...
What is the current status of trial NCT05128487?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2021-11-05. Estimated completion is 2025-05.
What conditions does trial NCT05128487 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma.
What interventions are being tested in trial NCT05128487?
The interventions under investigation include: Pembrolizumab (DRUG), NDI-101150 (DRUG).
Who is sponsoring clinical trial NCT05128487?
This trial is sponsored by Nimbus Saturn, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05128487 being conducted?
This trial has 19 study locations across Arizona, Connecticut, District of Columbia, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05128487's enrollment target sits among peer trials
106 227th of 454 higher than 228 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI